---
layout: default
title: Midazolam
parent: 僅模型預測 (L5)
nav_order: 90
evidence_level: L5
indication_count: 1
---

# Midazolam
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Midazolam: Repurposing Candidate — Evidence Pack Incomplete, Pending Data Completion

## One-Sentence Summary

Midazolam (DB00683) is a short-acting benzodiazepine sedative widely used for procedural sedation, anxiolysis, and anesthesia induction.
However, this Evidence Pack contains **no TxGNN-predicted new indications**, no safety records, and no regulatory data for Taiwan — the pipeline has critical data gaps that must be resolved before any repurposing evaluation can proceed.
This report documents the current state and defines the remediation steps required.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No indication data available in this Evidence Pack |
| Predicted New Indication | None — `predicted_indications` array is empty |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (model prediction data absent; no supporting studies retrieved) |
| Taiwan Market Status | ✗ Not marketed (0 licenses on record) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** — critical data gaps block evaluation |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available in the current Evidence Pack (`predicted_indications: []`), so a mechanism-to-indication reasoning chain cannot be constructed at this time.

Currently, detailed mechanism of action data is not available (DG002: Blocking — High severity). Based on general pharmacological knowledge, Midazolam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors, producing sedation, anxiolysis, anterograde amnesia, and anticonvulsant effects. However, this background information cannot substitute for a formal MOA entry and TxGNN graph-based prediction before a repurposing rationale can be written.

Once TxGNN predictions are retrieved and MOA data is sourced from DrugBank, this section should be completed to explain the mechanistic link between Midazolam's GABA-A modulation and any newly predicted indication.

---

## Taiwan Market Information

No license records were found. Midazolam is not currently marketed in Taiwan under any registered product, based on the TFDA query conducted on 2026-03-29 (result count: 0).

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** The TFDA package insert query returned a result (query log ID 4, status: success), but no warnings or contraindications were parsed into the Evidence Pack. Resolving DG001 (TFDA 仿單警語/禁忌, Severity: Blocking) is required before any safety screening can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Midazolam is missing all three foundational data layers — TxGNN predictions, mechanism of action, and safety profile — making it impossible to assess repurposing feasibility or patient risk at this stage.

**To proceed, the following is needed:**

1. **Resolve DG001 (Blocking):** Parse the TFDA package insert PDF (already retrieved, query log ID 4) to extract key warnings, contraindications, and black-box alerts — this is a prerequisite for S1 safety screening.
2. **Resolve DG002 (High):** Query the DrugBank API for DB00683 to populate `original_moa`, pharmacological class, and mechanism details.
3. **Re-run TxGNN pipeline:** With MOA and target data populated, re-execute the prediction model to generate `predicted_indications` with scores.
4. **Re-run evidence collection:** Once predicted indications are available, trigger the clinical trials (ClinicalTrials.gov) and literature (PubMed) evidence collection pipeline.
5. **Re-evaluate market status:** Clarify whether "未上市" reflects a genuine absence or a data retrieval gap — Midazolam is a commonly used drug internationally and its Taiwan status should be confirmed against the full TFDA database.
---

